Barclays analyst Emily Field raised the firm’s price target on Argenx to EUR 450 from EUR 405 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARGX:
- Argenx to acquire PRV for $102M
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- Argenx price target raised to EUR 480 from EUR 470 at JPMorgan
- argenx to Present at Upcoming Investor Conferences